INTRODUCTION: Despite the undeniable clinical efficacy of drug-eluting stents with durable polymers, concerns regarding their long-term safety have been raised, especially in more complex subsets. The Manipal-S Registry was designed to evaluate the safety and effectiveness of the biodegradable polymer coated Supralimus(®) Sirolimus-Eluting Coronary Stent for the treatment of coronary artery disease, across a wide range of patients who are treated in real-life clinical practice. METHODS: All the consecutive 116 patients who underwent single-vessel or multiple vessel percutaneous coronary interventions with the use of Supralimus(®) sirolimus-eluting stents between September 2009 and December 2010, were included in this study. Patients were clinically followed-up at 1, 9, 12 and 24 months post-procedure. All clinical, procedural, and follow-up information were collected and analysed. RESULTS: In total 116 patients, 126 lesions were implanted with 144 stents which had an average stent length of 25.8±8.0 mm. The incidences of any major adverse cardiac and cerebral events at 1, 9, 12 and 24 months were 0, 5 (4.3%), 8 (6.9%), and 10 (8.6%) respectively. CONCLUSION: These 24-month results clearly provide evidence for safety and effectiveness of the Supralimus(®) Sirolimus-eluting coronary stent system with the biodegradable polymer in real-life patients, even in those with acute myocardial infarctions.
INTRODUCTION: Despite the undeniable clinical efficacy of drug-eluting stents with durable polymers, concerns regarding their long-term safety have been raised, especially in more complex subsets. The Manipal-S Registry was designed to evaluate the safety and effectiveness of the biodegradable polymer coated Supralimus(®) Sirolimus-Eluting Coronary Stent for the treatment of coronary artery disease, across a wide range of patients who are treated in real-life clinical practice. METHODS: All the consecutive 116 patients who underwent single-vessel or multiple vessel percutaneous coronary interventions with the use of Supralimus(®) sirolimus-eluting stents between September 2009 and December 2010, were included in this study. Patients were clinically followed-up at 1, 9, 12 and 24 months post-procedure. All clinical, procedural, and follow-up information were collected and analysed. RESULTS: In total 116 patients, 126 lesions were implanted with 144 stents which had an average stent length of 25.8±8.0 mm. The incidences of any major adverse cardiac and cerebral events at 1, 9, 12 and 24 months were 0, 5 (4.3%), 8 (6.9%), and 10 (8.6%) respectively. CONCLUSION: These 24-month results clearly provide evidence for safety and effectiveness of the Supralimus(®) Sirolimus-eluting coronary stent system with the biodegradable polymer in real-life patients, even in those with acute myocardial infarctions.
Authors: Jonathan R Nebeker; Renu Virmani; Charles L Bennett; Jennifer M Hoffman; Matthew H Samore; Jorge Alvarez; Charles J Davidson; June M McKoy; Dennis W Raisch; Brian K Whisenant; Paul R Yarnold; Steven M Belknap; Dennis P West; Jonathan E Gage; Richard E Morse; Gordana Gligoric; Laura Davidson; Marc D Feldman Journal: J Am Coll Cardiol Date: 2005-12-01 Impact factor: 24.094
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Alain J Nordmann; Peter Hengstler; Bernd M Leimenstoll; Thomas Harr; James Young; Heiner C Bucher Journal: Eur Heart J Date: 2004-01 Impact factor: 29.983
Authors: Pedro A Lemos; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro; Eulógio E Martinez Journal: Catheter Cardiovasc Interv Date: 2009-11-01 Impact factor: 2.692
Authors: Aloke V Finn; Gaku Nakazawa; Michael Joner; Frank D Kolodgie; Erik K Mont; Herman K Gold; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-17 Impact factor: 8.311
Authors: Pedro A Lemos; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro Journal: EuroIntervention Date: 2012-05-15 Impact factor: 6.534
Authors: Lakshmana K Pendyala; Jinsheng Li; Toshiro Shinke; Sarah Geva; Xinhua Yin; Jack P Chen; Spencer B King; Keith A Robinson; Nicolas A F Chronos; Dongming Hou Journal: JACC Cardiovasc Interv Date: 2009-03 Impact factor: 11.195